Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTDLNGZ)

• DTT Name: Glucokinase (GCK) DTT Info
• Gene Name: GCK

Molecule-Related Drug & Molecule List

16 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AMG 151	DMGOFL3	Type-2 diabetes	5A11	Phase 2	[1]
AZD1656	DMUE90I	Diabetic complication	5A2Y	Phase 2	[2]
GK1-399	DMLFSMX	Diabetic complication	5A2Y	Phase 2	[3]
LY-2599506	DMMI0RH	Diabetic complication	5A2Y	Phase 2	[1]
LY-2608204	DM4EF9Y	Type-2 diabetes	5A11	Phase 2	[4]
PF-04937319	DMQMF4O	Type-2 diabetes	5A11	Phase 2	[5]
PF-04991532	DM94NBE	Diabetic complication	5A2Y	Phase 2	[6]
TTP399	DMBKQSZ	Type 2 diabetes	5A11	Phase 2	[7]
ADV-1002401	DMHIPF5	Type-2 diabetes	5A11	Phase 1	[8]
AZD5658	DMV6DF3	Diabetic complication	5A2Y	Phase 1	[9]
BMS-820132	DMCX0H7	Type-2 diabetes	5A11	Phase 1	[10]
DS-7309	DM7C4U9	Diabetic complication	5A2Y	Phase 1	[11]
HMS5552	DMRYM03	Type-2 diabetes	5A11	Phase 1	[12]
TAK-329	DMMWNQP	Diabetic complication	5A2Y	Phase 1	[13]
TTP-547	DMYFUOP	Diabetic complication	5A2Y	Phase 1	[14]
ZYGK-1	DM4IG16	Diabetic complication	5A2Y	Phase 1	[14]

3 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AZD6370	DMVZSRG	Type-2 diabetes	5A11	Discontinued in Phase 2	[2]
TTP-355	DMCEGN4	Diabetic complication	5A2Y	Discontinued in Phase 2	[15]
AZD-6714	DMHV3IW	Type-2 diabetes	5A11	Discontinued in Phase 1	[16]

6 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beta-D-Glucose	DM5IHYP	Discovery agent	N.A.	Investigative	[17]
GKA-23	DMIENSW	Diabetic complication	5A2Y	Investigative	[14]
GKA1	DM9P62Y	Discovery agent	N.A.	Investigative	[18]
Piragliatin	DMOE39X	Discovery agent	N.A.	Investigative	[19]
PSN-101	DMUROIY	Diabetic complication	5A2Y	Investigative	[20]
SKL-19014	DM5T4Y1	Non-insulin dependent diabetes	5A11	Investigative	[14]

References

• [1] This week in therapeutics Endocrine disease. SciBX 2(37); doi:10.1038/scibx.2009.1408. Sept. 24, 2009
• [2] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [3] Clinical pipeline report, company report or official report of vTv Therapeutics, NCT02405260.
• [4] Clinical pipeline report, company report or official report of Eli Lilly.
• [5] Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes. Diabetes Obes Metab. 2015 Aug;17(8):751-9.
• [6] The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats. PLoS One. 2014 May 23;9(5):e97139.
• [7] Clinical pipeline report, company report or official report of vTv Therapeutics.
• [8] The Hepatoselective Glucokinase Activator PF-04991532 Ameliorates Hyperglycemia without Causing Hepatic Steatosis in Diabetic Rats. PLoS One. 2014; 9(5): e97139.
• [9] Clinical pipeline report, company report or official report of AstraZeneca (2011).
• [10] Utilization of the Zucker Diabetic Fatty (ZDF) Rat Model for Investigating Hypoglycemia-related Toxicities. Toxicol Pathol. 2015 Aug;43(6):825-37.
• [11] Glucokinase alternative. SciBX 6(45); doi:10.1038/scibx.2013.1279. Nov. 21 2013
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] Clinical pipeline report, company report or official report of Takeda.
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2798).
• [15] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025266)
• [16] Glucokinase (GCK). SciBX 2(37); doi:10.1038/scibx.2009.1408. Sep. 24 2009
• [17] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [18] Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators. Diabetes. 2004 Mar;53(3):535-41.
• [19] Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study.J Clin Endocrinol Metab.2010 Nov;95(11):5028-36.
• [20] CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.